Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

1.5K
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.5K
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

24
Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
24
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

4.7K
The pathophysiology of pneumonia involves the following steps:
4.7K
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

4.2K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
4.2K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

1.4K
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.4K
Pneumonia IV: Management01:28

Pneumonia IV: Management

1.2K
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Strategies for Safer Cefepime Use to Prevent Neurotoxicity Using the Electronic Health Record.

Critical care explorations·2026
Same author

Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection or Disease or with Concurrent Organ Dysfunction: A Phase 2 Open Label Study.

Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada·2025
Same author

Managing Individual and Community Risk - Broad-Spectrum Antimicrobial Use.

NEJM evidence·2025
Same author

Status of HIV vaccine development: progress and promise.

Journal of the International AIDS Society·2025
Same author

High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302).

Annals of internal medicine·2025
Same author

NEJM Outbreaks Update - H5N1 in Indiana.

The New England journal of medicine·2025
Same journal

Nonsteroid treatment options in (pulmonary) sarcoidosis. When to consider and why?

Current opinion in pulmonary medicine·2026
Same journal

Multidisciplinary approach in cardiac sarcoidosis: to biopsy or not?

Current opinion in pulmonary medicine·2026
Same journal

Low diffusion capacity in pulmonary hypertension.

Current opinion in pulmonary medicine·2026
Same journal

Toward precision imaging in interstitial lung disease: advances in quantitative imaging and artificial intelligence.

Current opinion in pulmonary medicine·2026
Same journal

Oxygen therapy in interstitial lung disease - navigating benefit and burden.

Current opinion in pulmonary medicine·2026
Same journal

Preclinical and clinical advances in pulmonary hypertension associated with systemic sclerosis.

Current opinion in pulmonary medicine·2026
See all related articles

Related Experiment Video

Updated: May 2, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

14.6K

Pneumonia in the immunocompromised host.

Alyssa R Letourneau1, Nicolas C Issa, Lindsey R Baden

  • 1aDivision of Infectious Diseases, Brigham and Women's Hospital bDepartment of Medical Oncology, Dana-Farber Cancer Institute cHarvard Medical School, Boston, Massachusetts, USA.

Current Opinion in Pulmonary Medicine
|March 15, 2014
PubMed
Summary
This summary is machine-generated.

Diagnosing opportunistic pulmonary infections in immunocompromised hosts (ICHs) is crucial for reducing illness. Advances in diagnostics, including nucleic acid amplification and invasive procedures, enable earlier, targeted therapies for better outcomes.

More Related Videos

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
12:21

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

3.9K
A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

17.4K

Related Experiment Videos

Last Updated: May 2, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

14.6K
A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
12:21

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

3.9K
A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

17.4K

Area of Science:

  • Pulmonology
  • Infectious Diseases
  • Immunocompromised Host Management

Background:

  • Novel treatments increase survival, leading to more immunocompromised hosts (ICHs).
  • Opportunistic infections pose a significant risk to ICHs.

Purpose of the Study:

  • Review the spectrum of opportunistic infections in ICHs.
  • Discuss diagnostic and treatment approaches for pulmonary infections in ICHs.
  • Highlight advances in rapid and specific microbiologic diagnosis.

Main Methods:

  • Literature review of current and novel diagnostic modalities.
  • Focus on recent controversies and advances in diagnosing pulmonary infections.
  • Emphasis on early diagnosis and prompt treatment strategies.

Main Results:

  • Increasing spectrum of opportunistic infections observed in ICHs.
  • General approach for early diagnosis and treatment outlined.
  • Novel diagnostic modalities offer rapid and specific microbiologic diagnosis.

Conclusions:

  • Early diagnosis and prompt therapy reduce morbidity in ICHs.
  • Nonculture-based methods like nucleic acid amplification may enable earlier targeted therapy.
  • Invasive procedures remain essential for specific diagnosis in ICHs due to a broad differential diagnosis.